Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022
Cash & Equivalents	19.34	18.26
Cash & Cash Equivalents	19.34	18.26
Cash Growth	5.90%	-
Receivables	0.19	0.09
Other Current Assets	0.27	0.24
Total Current Assets	19.8	18.59
Property, Plant & Equipment	0.46	0.53
Other Long-Term Assets	0.01	0
Total Long-Term Assets	0.46	0.53
Total Assets	20.27	19.12
Accounts Payable	3.92	2.93
Current Debt	10.45	0.13
Other Current Liabilities	5	0
Total Current Liabilities	19.37	3.06
Long-Term Debt	0	8.86
Total Long-Term Liabilities	0	8.86
Total Liabilities	19.37	11.91
Total Debt	10.45	8.99
Debt Growth	16.32%	-
Retained Earnings	-105.5	-77.28
Comprehensive Income	-2.71	-2.79
Shareholders' Equity	2.22	7.79
Net Cash / Debt	8.89	9.28
Net Cash / Debt Growth	-4.18%	-
Net Cash Per Share	0.37	0.48
Working Capital	0.43	15.53
Book Value Per Share	0.09	0.40

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).